乌帕替尼单药治疗甲氨蝶呤应答不佳的类风湿关节炎患者:SELECT-MONOTHERAPY随机研究第260周结果
SELECT-MONOTHERAPY三期研究第260周结果显示,乌帕替尼单药治疗甲氨蝶呤应答不佳的类风湿关节炎患者长期安全性及疗效良好,未发现新的安全风险;乌帕替尼30 mg组带状疱疹、非黑色素瘤皮肤癌、肝病、中性粒细胞减少、淋巴细胞减少和肌酸激酶升高的发生率高于乌帕替尼15 mg组。
要点
- 648例随机患者中598例进入长期扩展研究,第260周时249例(41.6%)因不良事件等停药。
- 乌帕替尼30 mg组带状疱疹、非黑色素瘤皮肤癌等发生率高于乌帕替尼15 mg组。
- 基于NRI,持续乌帕替尼治疗者第260周低疾病活动度(CDAI≤10)和DAS28-CRP≤3.2的达标率均>39%。
核心结论
- 长期乌帕替尼治疗未发现新的安全风险;乌帕替尼单药治疗类风湿关节炎至第260周仍有效。
研究设计与样本
- III期SELECT-MONOTHERAPY随机研究(NCT02706951),648例对甲氨蝶呤应答不佳的类风湿关节炎患者随机继续甲氨蝶呤或接受乌帕替尼15 mg或30 mg单药治疗14周。
- 第14周起,继续甲氨蝶呤者按预设分配换用乌帕替尼15 mg或30 mg;随机接受乌帕替尼者继续治疗;方案修订后所有队列转为开放标签乌帕替尼15 mg。
- 安全性采用暴露调整事件率和发生率汇总;疗效采用观察数据和无效者插补(NRI)报告。
主要发现
- 648例随机患者中598例进入长期扩展研究;至第260周,249例(41.6%)中止研究药物,主要原因为不良事件(14.5%)、撤回知情同意(9.9%)、失访(3.3%)、疗效不足(2.2%)、COVID-19(0.7%)或其他原因(11.0%)。
- 乌帕替尼30 mg组带状疱疹、非黑色素瘤皮肤癌、肝病、中性粒细胞减少、淋巴细胞减少和肌酸激酶升高的发生率高于乌帕替尼15 mg组。
- 基于NRI,持续乌帕替尼治疗者第260周CDAI≤10的低疾病活动度达标率为乌帕替尼15 mg组93/217例、乌帕替尼30 mg组91/215例;DAS28-CRP≤3.2达标率为乌帕替尼15 mg组90/217例、乌帕替尼30 mg组94/215例。
- 从甲氨蝶呤换用乌帕替尼的患者疗效相似。
关键数值与推荐
- 低疾病活动度定义为CDAI≤10,基于NRI第260周乌帕替尼15 mg组93/217例、乌帕替尼30 mg组91/215例达标。
- DAS28-CRP≤3.2基于NRI第260周乌帕替尼15 mg组90/217例、乌帕替尼30 mg组94/215例达标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The phase III SELECT-MONOTHERAPY trial (NCT02706951) demonstrated the safety and efficacy of upadacitinib (UPA) monotherapy through 84 weeks in patients with rheumatoid arthritis who responded inadequately to methotrexate. Here we report week 260 results. METHODS: Patients were randomised to continue methotrexate or UPA 15 mg (UPA15) or 30 mg (UPA30) monotherapy for 14 weeks. From week 14, patients continuing methotrexate switched to UPA15 or UPA30 per prespecified assignment; patients randomised to UPA continued treatment. Following a protocol amendment, all cohorts switched to open-label UPA15. Safety was summarised using exposure-adjusted event and incidence rates. Efficacy was reported as observed and using non-responder imputation (NRI). RESULTS: Of 648 randomised patients, 598 entered the long-term extension. Of these, 249 (41.6%) discontinued study drug by week 260 primarily due to adverse events (14.5%), consent withdrawal (9.9%), lost to follow-up (3.3%), lack of efficacy (2.2%), COVID-19 (0.7%) or other reasons (11.0%). Rates of herpes zoster, non-melanoma skin cancer, hepatic disorder, neutropenia, lymphopenia and creatine kinase elevation were higher with UPA30 versus UPA15. Long-term UPA safety data were consistent with the established UPA safety profile. Based on NRI, >39% of patients treated continuously with UPA achieved low disease activity per Clinical Disease Activity Index ≤10 (UPA15, n=93/217; UPA30, n=91/215) and 28-joint Disease Activity Score using C reactive protein ≤3.2 (UPA15, n=90/217; UPA30, n=94/215) at week 260. Efficacy was similar among patients switching from methotrexate to UPA. CONCLUSION: No new safety risks were identified with long-term UPA treatment. UPA monotherapy was efficacious in treating rheumatoid arthritis through week 260. TRIAL REGISTRATION NUMBER: NCT02706951.
引用
- Smolen JS, Emery P, Rigby W, et al. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study. RMD Open. 2025. PMID: 40350200. doi:10.1136/rmdopen-2024-005051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。